Key result
Extended thromboprophylaxis under NICE NG89 guidelines faces debate over clinical justification and cost-effectiveness.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Extended thromboprophylaxis justification questioned; leaves open cost-effectiveness and routine NICE NG89 adoption pending stronger evidence.
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.
No takes yet. Share an insight, caveat, or question.
Stansby et al. (2019) studied this question. Extended pharmacological thromboprophylaxis under NICE NG89 guidelines is debated regarding its clinical justification and cost-effectiveness in a rebuttal response to the British Society for Haematol.
Synapse has enriched 10 related papers. Consider them for comparative context: